Success Metrics

Clinical Success Rate
57.1%

Based on 4 completed trials

Completion Rate
57%(4/7)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Terminated
3(38%)

Phase Distribution

Ph phase_1
3
38%
Ph phase_2
5
63%

Phase Distribution

3

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
5(62.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(4)
Terminated(3)
Other(1)

Detailed Status

Completed4
Terminated3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
57.1%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (37.5%)
Phase 25 (62.5%)

Trials by Status

terminated338%
completed450%
unknown113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_1

Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function

NCT06736223
terminatedphase_1

Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease

NCT00792740
terminatedphase_2

Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma

NCT00792506
terminatedphase_2

Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia

NCT00792831
completedphase_1

Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma

NCT00792467
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06736223Phase 1

Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function

Completed
NCT00792740Phase 1

Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease

Terminated
NCT00792506Phase 2

Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma

Terminated
NCT00792831Phase 2

Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia

Terminated
NCT00792467Phase 1

Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma

Completed
NCT00570661Phase 2

Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis

Completed
NCT00606307Phase 2

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

Completed
NCT00442182Phase 2

The Efficacy and Safety of ITF2357 in AIS

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8